



## SUCCESSFUL CAPITAL RAISING TO SUPPORT ALZHEIMERS RESEARCH

- **Heavily oversubscribed placement raises \$10.0m for Actinogen Medical**
- **A Shareholder Share Purchase Plan (SPP) will raise an additional \$1.0m**
- **Funds to support Phase II trial of Xanamem™, our promising Alzheimer's drug**
- **Xanamem suppresses cortisol production. Excess cortisol associated with memory loss and amyloid plaques - hallmarks of Alzheimer's disease.**

**Sydney, 24 April 2015:** Actinogen Limited (Actinogen Medical, ASX: ACW) is pleased to announce that \$10.0m was successfully raised through its recent placement to sophisticated and institutional investors. \$10.0 million via the issue of 105,263,158 ordinary fully paid Actinogen Medical shares at an issue price of 9.5 cents per share. The placement was co-lead by KTM Capital and Forrest Capital and was heavily over-subscribed.

The SPP allows for current shareholders to also participate at the same price as the placement. The SPP will be available to all of our current shareholders on a **first-come first-served** basis and **capped to \$1.0m** and is at the final discretion of Board of Directors. Further details of the SPP, including key dates, will be contained in the SPP offer to be dispatched to shareholders shortly. The record date for the SPP is 23 April 2015.

Proceeds from this capital raise will be used to support the IND filing with US FDA and the planned Phase 2 study of Xanamem™ in patients with early Alzheimer's disease. The Phase 2 study is planned to start in 2016 and for it to run in Australia/New Zealand, the USA and the UK.

The Board is particularly excited by the potential of Actinogen Medical, and our lead research candidate Xanamem™. Xanamem™ represents a novel approach to treating Alzheimer's disease – a condition with a significant unmet medical need that threatens to place a huge burden on society. It blocks the production of cortisol – the "stress hormone" – which appears to contribute to the cognitive impairment, amyloid plaques and neural death - hallmarks of Alzheimer's disease.

Alzheimer's disease is the most common form of dementia and has a debilitating effect on patients and their loved ones. Alzheimer's is also growing rapidly: it is now the second leading cause of death in Australia behind ischaemic heart disease and the American Alzheimer's Association estimates that the direct healthcare cost of the disease was \$US250 billion in 2013, and by 2050, the cost of care for people with the disease is expected to be over \$US1 trillion, outstripping the cost of treating all other diseases.

With the development of our promising lead compound Xanamem™, we are hopeful of finding an effective treatment for Alzheimer's disease in its early stage. The proceeds from this placement will support this ongoing research.

Actinogen Medical Chairman Mr Martin Rogers said:

*“We are delighted with the strong level of support for the Placement, which is a validation of the Company’s development plans for Xanamem™ and its potential to provide a commercially viable treatment option for Alzheimer’s dementia. The SPP allows for current shareholders to also participate at the same price as the placement. On behalf of the Board of Directors we thank the investors who participated with KTM Capital and Forrest Capital and we look forward to providing updates on the progress of Xanamem™’s development in due course.”*

**ENDS**


**Actinogen Medical**

Martin Rogers

Chairman

P: +61 2 8964 7401

E: [martin.rogers@actinogen.com.au](mailto:martin.rogers@actinogen.com.au)

 [@MartinFRogers](https://twitter.com/MartinFRogers)

**About Actinogen Medical**

Actinogen Medical is focused on the treatment of Alzheimer’s disease and mild cognitive impairment, a transitional stage of cognitive impairment between normal aging and the more serious condition of Alzheimer’s dementia. It is developing a novel drug to treat the condition and other age-related neurodegenerative diseases. The lead candidate drug Xanamem™, blocks the development of cortisol which appears to contribute to cognitive impairment and amyloid plaques – hallmarks of Alzheimer’s disease. The Company is currently undertaking a second Phase I multiple ascending dose trial in healthy volunteers with results in mid-2015 and plans to undertake a Phase II study in 2016.